REG - Cambridge Cognition - £1 million contract for late phase cancer trial

Cambridge Cognition HoldingsAnnouncement

09/07/2021 07:00

RNS Number : 6873E
  
Cambridge Cognition Holdings PLC
  
09 July 2021
  
 

 
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
 
Cambridge Cognition wins £1 million contract 
as the cognitive assessment partner for late phase cancer trial
 
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a £1 million contract as the cognitive assessment partner for a late phase cancer trial.  This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products.  The revenue from the contract is expected to be recognised over the next six years. 
 
Oncology is the leading therapeutic area for drug development and accounted for nearly a third of clinical trials in 20201.  This contract positions the Company in the world's most consistently active disease space with a client that is committed to developing oncology therapeutics. 
 
Cancer survival has doubled in the last 40 years in the UK2.  With patients now living longer there is a greater focus on limiting potentially detrimental long-term side effects of both diagnosis and treatment.  One key area is cognitive impairment, for which deficits have been reported in 90% of patients with brain tumours and an estimated 30% of patients following chemotherapy3. 
 
Cognitive decline associated with cancer most notably affects attention, memory, and executive function.  The pharmaceutical company has selected Cambridge Cognition as the cognitive assessment provider for its pivotal oncology trial as they believe that CANTABTM cognitive assessments have the sensitivity to measure these distinct processes.  Consequently, CANTABTM will be used worldwide to determine preservation or improvement in cognitive function across all 150 trial sites.
 
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
"Earlier detection and advances in treatment have to led to considerable improvements in cancer survival rates and, at the same time, increased attention on the cognitive side-effects.  This pharmaceutical client has a long-standing commitment to improving outcomes for cancer patients and we are delighted to be supporting their efforts.  We expect that this could become a considerable growth area for Cambridge Cognition in the future."
 
References
1.        GlobalData. 2020. Oncology dominates clinical trials activity in 2020. https://www.globaldata.com/oncology-dominates-clinical-trials-activity-in-2020-says-globaldata/ 
2.        Cancer Research UK. Cancer survival for all cancers combined. https://www.cancerresearchuk.org/health-professional/cancer-statistics/survival#heading-Zero 
3.        Assessment and management of cognitive symptoms in patients with brain tumours, Parsons & Dietrich, American Society of Clinical Oncology Educational Book 41 (May 19, 2021) e90-e99.x`
 
For further information, contact: 
 



Cambridge Cognition Holdings Plc
Matthew Stork, Chief Executive Officer
Michael Holton, Chief Financial Officer 


Tel: 012 2381 0700
press@camcog.com




finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks
Alice Lane / Charlotte Sutcliffe 


Tel: 020 7220 0500
(Corporate Finance)
(Corporate Broking)




Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant


Tel: 020 3903 7715
 




IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Graham Herring / Zach Cohen


Tel: 020 3934 6630
 



 
Notes to Editors
 
About Cambridge Cognition
 
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
 
For further information visit www.cambridgecognition.com
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
CNTFZGGNLRMGMZM